Humana/$HUM
1D1W1MYTD1Y5YMAX
Capital at risk
About Humana
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
- Ticker
- $HUM
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 67,060
- Headquarters
- Louisville, United States
- Website
- www.humana.com
Humana Metrics
BasicAdvanced
$48B
37.58
$10.59
0.75
$3.54
0.89%
Price and volume
Market cap
$48B
Beta
0.75
52-week high
$428.88
52-week low
$163.11
Average daily volume
981K
Dividend rate
$3.54
Financial strength
Current ratio
1.742
Quick ratio
1.285
Long term debt to equity
0.621
Total debt to equity
0.757
Dividend payout ratio (TTM)
33.62%
Interest coverage (TTM)
4.76%
Profitability
EBITDA (TTM)
3,596
Gross margin (TTM)
13.65%
Net profit margin (TTM)
0.88%
Operating margin (TTM)
2.30%
Effective tax rate (TTM)
18.71%
Revenue per employee (TTM)
$2,170,000
Management effectiveness
Return on assets (TTM)
3.90%
Return on equity (TTM)
6.89%
Valuation
Price to earnings (TTM)
37.582
Price to revenue (TTM)
0.328
Price to book
2.49
Price to tangible book (TTM)
6.33
Price to free cash flow (TTM)
24.552
Free cash flow yield (TTM)
4.07%
Free cash flow per share (TTM)
16.208
Dividend yield (TTM)
0.89%
Forward dividend yield
0.89%
Growth
Revenue change (TTM)
18.33%
Earnings per share change (TTM)
-18.81%
3-year revenue growth (CAGR)
13.85%
10-year revenue growth (CAGR)
10.33%
3-year earnings per share growth (CAGR)
-26.62%
10-year earnings per share growth (CAGR)
4.99%
3-year dividend per share growth (CAGR)
1.91%
10-year dividend per share growth (CAGR)
11.80%
What the Analysts think about Humana
Analyst ratings (Buy, Hold, Sell) for Humana stock.
Analyst projections of the future price of Humana stock.
Bulls say / Bears say
Humana held its 2026 adjusted EPS guidance at least $9 after second-quarter medical costs came in as expected. The 91.2% benefit ratio and roughly 25% individual Medicare Advantage membership growth suggest its pricing, retention and cost controls are beginning to stabilise the core business. (Reuters, Humana)
The company is targeting a sustainable 3% pretax margin in individual Medicare Advantage by 2028. Exiting lower-return plans and concentrating on products with stronger value-based care participation could improve margins even if total membership grows more slowly. (Healthcare Dive, Humana)
CenterWell Senior Primary Care patients grew by 27% year to date, while Humana won a statewide Illinois Medicaid managed-care contract starting in 2027. These developments broaden the company’s healthcare-services and Medicaid growth platforms beyond its existing Medicare Advantage book. (Humana)
The planned 2027 exits will affect roughly 600,000 Medicare Advantage members, creating a material retention and revenue risk. Humana has recaptured only just over 40% of members affected by its previous exits and expects a similar result this time. (Healthcare Dive, Becker's Hospital Review)
Data summarised monthly by Lightyear AI. Last updated on 25 Sept 2026.
Humana Financial Performance
Revenues and expenses
Humana Earnings Performance
Company profitability
Upcoming events
Humana News
AllArticlesVideos
New Humana research finds association between pharmacy care coordination services and improved health outcomes for cancer patients
Business Wire1 week ago
Humana Board Declares Payment of Quarterly Dividend to Stockholders
Business Wire4 weeks ago
As Health Insurers Gain Handle On Costs, Stocks Are Soaring Again
Forbes1 month ago
Funds containing Humana
AllEURUSDGBP
Fund name | Fund size | $HUM weighting |
|---|---|---|
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 0.82% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.74% |
iShares Ageing Population€AGED | €822M | 0.51% |
iShares MSCI USA SRI$SUAS | $3.4B | 0.32% |
iShares MSCI USA SRI€QDVR | €2.9B | 0.32% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.